Format

Send to

Choose Destination
Eur J Surg Oncol. 2018 Oct;44(10):1469-1478. doi: 10.1016/j.ejso.2018.06.012. Epub 2018 Jun 23.

A systematic analysis highlighting deficiencies in reported outcomes for patients with stage IV colorectal cancer undergoing palliative resection of the primary tumour.

Author information

1
Newcastle Centre of Bowel Disease, Royal Victoria Infirmary, Newcastle upon Tyne, UK; Clinical Trials Research Unit, University of Leeds, UK. Electronic address: deena_harji@hotmail.com.
2
Clinical Effectiveness Unit, Royal College of Surgeons, London, UK.
3
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
4
Department of Surgery, University Hospitals Birmingham, Birmingham, UK.
5
Peritoneal Malignancy Institute, North Hampshire Hospital, Hampshire Hospital Foundation Trust, Basingstoke, UK.
6
Clinical Trials Research Unit, University of Leeds, UK.
7
Department of Colorectal Surgery, Addenbrooke's Hospital, Cambridge, UK.

Abstract

BACKGROUND:

Management of the primary tumour in the presence of unresectable metastatic colorectal cancer (mCRC) is controversial. The role of primary tumour resection (PTR) has been investigated by a number of retrospective cohort studies, with a number on going randomised controlled trials. The aim of this study was to identify the clinical and patient-reported outcomes currently reported in studies that evaluate the role of PTR in mCRC.

METHODS:

Literature searches were performed in MEDLINE (via OvidSP) (1966-June 2017), EMBASE (via OvidSP) and the Cochrane Library using terms related to colorectal cancer and primary tumour resection. All studies documenting outcomes following palliative PTR were included. Eligible articles were assessed using the Risk of Bias In Non-Randomised Studies of Intervention (ROBINS-I) tool.

RESULTS:

Of 11,209 studies screened, 59 non-randomised studies reporting outcomes on 331,157 patients were included. Patient characteristics regarding performance status and co-morbidity were recorded in 26 (44.1%) and 17 (28.8%) studies. The chemotherapy regime used was reported in 27 (45.8%) studies. The operative setting and the operative approach was reported in 42 (71%) and 14 (23.7%) studies. Post-operative mortality and morbidity were reported in 33 (55.9%) and 35 (59.3%) studies. Overall survival was reported in 49 (83.1%) studies, with 5 different definitions identified. Quality of life was only reported in 1 (1.7%) study.

CONCLUSION:

This study demonstrates significant heterogeneity in the selection and definition of outcomes reported following PTR in mCRC. There is significant heterogeneity with a significant under-reporting of important outcomes such as treatment related adverse events and patient reported outcomes.

KEYWORDS:

Metastatic colorectal cancer; Primary tumour resection

PMID:
30007475
DOI:
10.1016/j.ejso.2018.06.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center